Coverage · 2026 plan year
40% of commercial plans now cover a GLP-1
About 40% of commercial insurance plans now cover at least one GLP-1 for weight management, up from roughly 25% in 2024, and around 55% of large employer groups are taking the obesity coverage rider for 2026. If you have employer insurance, the odds you are covered are far better than they were two years ago — and better than most people assume.
Check this before any cash price
Every figure on this site is a cash price. If your plan covers an approved GLP-1, your copay is the number that matters and it can be far below anything in our database, where the floor is $169 a month all-in for tirzepatide.
Coverage varies by employer group as much as by insurer, so a colleague's answer at a different company tells you nothing about yours. Ask your own plan, in writing, whether anti-obesity medications are a covered benefit.
The other doors: indications beyond obesity
This is the part most people miss. Newer indications create coverage pathways for patients who do not qualify on obesity alone. Zepbound has been approved for obstructive sleep apnea since December 2024 and some plans cover it on that basis. Noncirrhotic MASH indications are eligible for Part D coverage.
If you have a qualifying condition alongside your weight, that condition may be the route in — and it may be documented in your chart already without anyone having connected it to a prior authorisation.
What the criteria usually require
A qualifying diagnosis, a BMI threshold — commonly 30, or 27 with at least one obesity-related comorbidity — and documentation of a lifestyle intervention attempt. Most denials are not judgements that the medicine would not help; they are findings that the submitted paperwork did not match the plan's written criteria.
That makes them mechanical to fix. Get the criteria, answer them item by item with dated documentation, and appeal against the specific stated reason. Our insurance and appeals guide has the full sequence including external review.
Compounded products and coverage
Compounded GLP-1s are generally not covered, because they are not FDA-approved products. Paying cash for a compounded product does not build any record that helps a future authorisation for the approved one — it is a different transaction entirely, not a stepping stone.
Verified . Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Questions
Does insurance cover GLP-1s in 2026?
About 40% of commercial plans cover at least one GLP-1 for weight management, up from roughly 25% in 2024, and around 55% of large employer groups are taking the obesity rider for 2026. Coverage varies by employer group, so ask your own plan.
What BMI do you need for GLP-1 insurance coverage?
Commonly a BMI of 30, or 27 with at least one obesity-related comorbidity, alongside a qualifying diagnosis and documentation of a lifestyle intervention attempt. Exact criteria are plan-specific and should be requested in writing.
Can I get GLP-1 coverage without an obesity diagnosis?
Sometimes. Zepbound has been approved for obstructive sleep apnea since December 2024 and some plans cover it on that basis; noncirrhotic MASH indications are eligible for Part D coverage. A qualifying condition alongside weight may be the route in.
Does insurance cover compounded GLP-1s?
Generally no, because compounded products are not FDA approved. Paying cash for compounded product does not build a record toward a future authorisation for the approved medicine.